Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo. Keytruda (pembrolizumab) in the ...

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, offering a more effective option for many patients.

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Keytruda plus chemotherapy did not negatively affect health-related quality of life in cervical cancer patients, regardless of Avastin addition. The KEYNOTE-826 trial involved 587 patients, assessing ...

Many think the next standard cancer treatment will pair two innovations.

WSW, NY, July 29th, 2026, FinanceWirePembrolizumab is the world's best-selling cancer drug at $31.7 billion in 2025 revenue, ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti ...

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ...

Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.

CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...